

## gp100/tyrosinase/MLANA Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0453

DESCRIPTION	
Product Name	gp100/tyrosinase/MLANA Circular RNA for Cancer Vaccine Research
Gene Name	gp100/tyrosinase/MLANA
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	Synthetic Melanoma-Associated Antigens Vaccine
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	gp100/tyrosinase/MLANA
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Ionizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	Synthetic Melanoma-Associated Antigens Vaccine

epitopes with the vaccine epitope peptides, resulting in tumor cell lysis. (NCIT\_C48639).

#### Background

Description: A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share